BioSpace News Archive

Zosano Pharma Corporation, a clinical-stage biopharmaceutical company, announced that new post-hoc efficacy analyses of QtryptaTM, Zosano’s lead investigational product candidate for the acute treatment of migraine, will be presented as a virtual oral presentation on the 2020 American Headache Society’s Virtual Annual Scientific Meeting Platform.

Phase 3 ANDROMEDA study investigated the first and only subcutaneous anti-CD38 monoclonal antibody in treatment of rare multi-system disease with a high unmet medical need and for which there are currently no approved therapies Data selected as late-breaking abstract and featured in press briefing at European Hematology Association (EHA) Annual Congress [13-June-2020]

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen Research & Development, LLC (Janssen) presented data from its Phase III ANDROMEDA (AMY3001) study of subcutaneous (SC) daratumumab utilizing ENHANZE ® in combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD) for patients with newly diagnosed li

Campaign features stories of hope, tears, and encouragement from a diverse group of 9 individuals with metastatic breast cancer [MBC] New website and mobile app provide vital information and resources to help people facing MBC create a personal support network and feel less isolated [13-June-2020] BUFFALO, N.Y. and CHICAGO , June 13, 2020 /PRNewswire/ -- A

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today presented six posters for Zynquista TM (sotagliflozin) at the virtual 80 th American Diabetes Association (ADA) Scientific Sessions including additional efficacy and safety data patients with type 2 diabetes and moderate and severe renal impairment. Phase 3 CKD-3 Study In the Phase 3, multicenter, randomized, double-blind, placebo-controlled CKD-3 study, sotagliflozin was tes

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today presented positive real-world data from early use of the t:slim X2™ insulin pump with Control-IQ™ advanced hybrid closed loop technology, demonstrating statistically significant improvements in sensor Time in Range (70-180 mg/dL) in people living with both type 1 and type 2 diabetes with no increase in hypoglycemia (<

- Phase 3 VIALE-A study showed a 34 percent reduction in the risk of death in AML patients who were ineligible for intensive chemotherapy treated with venetoclax plus azacitidine compared to azacitidine plus placebo - The median overall survival (OS) for patients in the venetoclax arm was 14.7 months versus 9.6 months in the placebo arm - Patients in the venetoclax arm showed more than double the rate of composite complete remission (CR + CRi) (66.4 percent) compared to those

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced that it has entered into a non-exclusive Licensing Agreement with Gilead Sciences, Inc. (Gilead) that will grant Dr. Reddy’s the right to register, manu

Phase III VIALE-A study showed Venclexta plus azacitidine helped people with the most common type of aggressive adult leukemia live longer compared to azacitidine alone – – Data will be presented as a late-breaking abstract at the 25th European Hematology Association Virtual Congress –

People using Abbott’s FreeStyle Libre, a sensor-based glucose monitoring system, experienced a considerable decrease in ketoacidosis-related hospitalizations—52% for type 1 diabetes and 47% for typ